Towards Gene Therapy for Haemophilia B

  • Ann Gerrard
Conference paper
Part of the NATO ASI Series book series (volume 94)

Abstract

Haemophilia B is an X-linked bleeding disorder affecting about 1 in 30,000 males. It is caused by mutations in the gene for blood clotting factor IX, which results in reduced amounts of functional factor IX in plasma. This leads to failure of the blood clotting cascade, which results in life-threatening bleeding episodes. Current treatment of haemophiliacs involves the intravenous injection of factor IX which has been purified from pooled human donor plasma. Although the haemostatic effectiveness of this treatment is well established and there is now a minimal risk of HIV infection, there is still the possibility that hepatitis B and C may be transmitted. Furthermore, treatment is given in response to bleeding episodes and not prophylactically. Gene therapy for haemophilia B would provide the patient with a permanent supply of factor IX, so that bleeds would be prevented rather than merely treated. Also frequent injections would no longer be necessary, thus improving the life-style of patients.

Keywords

Hepatitis Polypeptide Neomycin 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Armentano D, Thompson AR, Darlington G and Woo SLC (1990) Expression of human factor IX in rabbit hepatocytes by retrovirus-mediated gene transfer: potential for gene therapy of haemophilia B. Proc Natl Acad Sci USA 87: 6141–6145PubMedCrossRefGoogle Scholar
  2. Axelrod JH, Read MS, Brinkhous KM and Verma IM (1990) Phenotypic correction of factor IX deficiency in skin fibroblasts of haemophiliac dogs. Proc Natl Acad Sci USA 87: 5173–5177PubMedCrossRefGoogle Scholar
  3. Dai Y, Roman M, Naviaux RK and Verma IM (1992) Gene therapy via primary myoblasts: long term expression of factor IX protein following transplantation in vivo. Proc Natl Acad Sci USA 89:10892–10895PubMedCrossRefGoogle Scholar
  4. Gerrard AJ, Austen DEG and Brownlee GG (1992) Subcutaneous injection of factor IX for the treatment of haemophilia B. Br J Haematol 81: 610–613PubMedCrossRefGoogle Scholar
  5. Gerrard AJ, Hudson DL, Brownlee GG and Watt FM (1993) Towards gene therapy for haemophilia B using primary keratinocytes. Nature Genetics 3: 180–183.PubMedCrossRefGoogle Scholar
  6. Kay MA, Rothenberg S, Landon CN et al (1993) In vivo therapy of haemophilia B: sustained partial correction in factor IX-deficient dogs. Science 262:117–119PubMedCrossRefGoogle Scholar
  7. Kay MA, Landon CN, Rothenberg S et al (1994) In vivo hepatic gene therapy: complete albeit transient correction of factor IX deficiency in haemophilia B dogs. Proc Natl Acad Sci USA 91: 2353–2357PubMedCrossRefGoogle Scholar
  8. Miyanohara A, Johnson PA, Elam RL, Dai Y, Witztum JL, Verma I and Friedmann T (1992) Direct gene transfer to the liver with herpes simplex virus type 1 vectors: transient production of physiologically relevant levels of circulating factor IX. New Biol 4: 238–246PubMedGoogle Scholar
  9. Palmer TD, Thompson AR and Miller AD (1989) Production of human factor IX in animals by genetically modified skin fibroblasts: potential therapy for haemophilia B. Blood 73: 438–445PubMedGoogle Scholar
  10. Perales JC, Ferkol T, Beegen H, Ratnoff OD, Hanson RW (1994) Gene transfer in vivo: sustained expression and regulation of genes introduced into the liver by receptor-targeted uptake. Proc Natl Acad Sci USA 91:4086–4090PubMedCrossRefGoogle Scholar
  11. Smith TAG, Mehaffrey MG, Kayda DB et al (1993) Adenovirus mediated expression of therapeutic plasma levels of human factor IX in mice. Nature Genetics 5: 397–402PubMedCrossRefGoogle Scholar
  12. Yao SN, Wilson JM, Nabel EG, Kurachi S, Hachiya HL and Kurachi K (1991) Expression of human factor IX in rat capillary endothelial cells: towards somatic gene therapy for haemophilia B. Proc Natl Acad Sci USA 88: 8101–8105PubMedCrossRefGoogle Scholar
  13. Yao SN and Kurachi K (1992) Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc Natl Acad Sci USA 89:3357–3361PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 1996

Authors and Affiliations

  • Ann Gerrard
    • 1
  1. 1.Sir William Dunn School of PathologyUniversity of OxfordOxfordUK

Personalised recommendations